Overview
Compare with AbioMed, Tandem Diabetes Care, Inc. or NuVasive, or pick any stock.
- TickerEMBC on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersWilmington, United States2
- Incorporated inDE4
- Business address300 Kimball Drive, Suite 300, Parsippany, Nj 070544
- Filer categoryLarge accelerated filer4
- Legal formCorporation2
- LEI549300RPG8GXVDHNXZ622
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 60665562
See how the biggest companies compare on our leaderboards
Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
62.6%Gross margin3
22.4%Operating margin3
8.8%Net margin3
-3.8%Revenue growth, 20253
$182.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Pen Needles brought in 73% of the revenue Embecta Corp. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Pen Needles | $829.2M | $844.4M | $784.1M |
| Safety | $126.3M | $129.4M | $137.8M |
| Syringes | $138.1M | $126.2M | $124.6M |
| Manufacturing Facility | $13.0M | $12.8M | $19.9M |
| Product and Service, Other | $14.2M | $10.3M | $14.0M |
Regions
United States brought in 54% of the revenue Embecta Corp. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $601.4M | $607.2M | $579.1M |
| Outside the United States | $519.4M | $515.9M | $501.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue37¢$403.6M
- Research and development3¢$37.3M
- Selling, general and admin31¢$332.0M
- Other costs16¢$171.2M
- Income tax4¢$40.9M
- Profit9¢$95.4M
Out of $1.1B in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending5¢$9.3M
- Dividends paid18¢$35.0M
- Kept or used elsewhere77¢$147.4M
Out of $191.7M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Revenues | $1.1B | $1.1B | $1.1B |
| Cost of products sold | $403.6M | $387.9M | $370.9M |
| Gross Profit | $676.8M | $735.2M | $749.9M |
| Selling and administrative expense | $332.0M | $365.1M | $341.3M |
| Research and development expense | $37.3M | $78.8M | $85.2M |
| Impairment expense | $0 | $0 | $2.5M |
| Other operating expenses | $65.4M | $124.5M | $99.4M |
| Total Operating Expenses | $434.7M | $568.4M | $528.4M |
| Operating Income | $242.1M | $166.8M | $221.5M |
| Interest expense, net | -$107.3M | -$112.3M | -$107.0M |
| Other income (expense), net | $1.5M | -$10.3M | -$8.8M |
| Income Before Income Taxes | $136.3M | $44.2M | $105.7M |
| Income tax provision (benefit) | $40.9M | -$34.1M | $35.3M |
| Net Income | $95.4M | $78.3M | $70.4M |
| Basic (in dollars per share) | $1.64 | $1.36 | $1.23 |
| Diluted (in dollars per share) | $1.62 | $1.34 | $1.22 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash and equivalents | $225.5M | $267.5M | ||
| Restricted cash | $3.1M | $6.7M | ||
| Trade receivables, net (net of allowance for doubtful accounts of $1.8 million and $2.8 million as of September 30, 2025 and September 30, 2024, respectively) | $145.6M | $193.0M | ||
| Materials | $50.0M | $40.4M | ||
| Work in process | $11.7M | $4.8M | ||
| Finished products | $116.9M | $126.3M | ||
| Total Inventories | $178.6M | $171.5M | ||
| Amounts due from Becton, Dickinson and Company | $3.3M | $53.8M | ||
| Prepaid expenses and other | $75.3M | $68.5M | ||
| Total Current Assets | $631.4M | $761.0M | ||
| Property, Plant and Equipment, Net | $257.2M | $290.4M | ||
| Goodwill and Intangible Assets | $22.4M | $23.7M | ||
| Deferred Income Taxes and Other Assets | $179.9M | $210.2M | ||
| Total Assets | $1.1B | $1.3B | ||
| Accounts payable | $74.2M | $91.0M | ||
| Accrued expenses | $98.9M | $134.2M | ||
| Amounts due to Becton, Dickinson and Company | $16.3M | $42.5M | ||
| Salaries, wages and related items | $49.4M | $66.7M | ||
| Current debt obligations | $9.5M | $9.5M | ||
| Current finance lease liabilities | $3.4M | $3.4M | ||
| Income taxes | $9.8M | $26.7M | ||
| Total Current Liabilities | $261.5M | $374.0M | ||
| Deferred Income Taxes and Other Liabilities | $62.6M | $54.1M | ||
| Long-Term Debt | $1.4B | $1.6B | ||
| Non Current Finance Lease Liabilities | $28.7M | $30.2M | ||
| Common stock, $0.01 par value Authorized - 250,000,000 Issued and outstanding - 58,496,113 as of September 30, 2025 and 57,707,285 as of September 30, 2024 | $600.0K | $600.0K | ||
| Additional paid-in capital | $80.0M | $52.5M | ||
| Accumulated deficit | -$445.6M | -$498.6M | ||
| Accumulated other comprehensive loss | -$285.6M | -$292.8M | ||
| Total Equity | -$650.6M | -$738.3M | -$821.7M | -$891.4M |
| Total Liabilities and Equity | $1.1B | $1.3B | ||
| Trade receivables, allowance for doubtful accounts | $1.8M | $2.8M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, issued (in shares) | 58.5M shares | 57.7M shares | ||
| Common stock, outstanding (in shares) | 58.5M shares | 57.7M shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash and equivalents | $225.5M | $267.5M | ||
| Restricted cash | $3.1M | $6.7M | ||
| Trade receivables, net (net of allowance for doubtful accounts of $1.8 million and $2.8 million as of September 30, 2025 and September 30, 2024, respectively) | $145.6M | $193.0M | ||
| Materials | $50.0M | $40.4M | ||
| Work in process | $11.7M | $4.8M | ||
| Finished products | $116.9M | $126.3M | ||
| Total Inventories | $178.6M | $171.5M | ||
| Amounts due from Becton, Dickinson and Company | $3.3M | $53.8M | ||
| Prepaid expenses and other | $75.3M | $68.5M | ||
| Total Current Assets | $631.4M | $761.0M | ||
| Property, Plant and Equipment, Net | $257.2M | $290.4M | ||
| Goodwill and Intangible Assets | $22.4M | $23.7M | ||
| Deferred Income Taxes and Other Assets | $179.9M | $210.2M | ||
| Total Assets | $1.1B | $1.3B | ||
| Accounts payable | $74.2M | $91.0M | ||
| Accrued expenses | $98.9M | $134.2M | ||
| Amounts due to Becton, Dickinson and Company | $16.3M | $42.5M | ||
| Salaries, wages and related items | $49.4M | $66.7M | ||
| Current debt obligations | $9.5M | $9.5M | ||
| Current finance lease liabilities | $3.4M | $3.4M | ||
| Income taxes | $9.8M | $26.7M | ||
| Total Current Liabilities | $261.5M | $374.0M | ||
| Deferred Income Taxes and Other Liabilities | $62.6M | $54.1M | ||
| Long-Term Debt | $1.4B | $1.6B | ||
| Non Current Finance Lease Liabilities | $28.7M | $30.2M | ||
| Common stock, $0.01 par value Authorized - 250,000,000 Issued and outstanding - 58,496,113 as of September 30, 2025 and 57,707,285 as of September 30, 2024 | $600.0K | $600.0K | ||
| Additional paid-in capital | $80.0M | $52.5M | ||
| Accumulated deficit | -$445.6M | -$498.6M | ||
| Accumulated other comprehensive loss | -$285.6M | -$292.8M | ||
| Total Equity | -$650.6M | -$738.3M | -$821.7M | -$891.4M |
| Total Liabilities and Equity | $1.1B | $1.3B | ||
| Trade receivables, allowance for doubtful accounts | $1.8M | $2.8M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, issued (in shares) | 58.5M shares | 57.7M shares | ||
| Common stock, outstanding (in shares) | 58.5M shares | 57.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net income | $95.4M | $78.3M | $70.4M |
| Depreciation and amortization | $40.7M | $36.2M | $32.6M |
| Amortization of debt issuance costs | $9.1M | $6.9M | $6.4M |
| Amortization of cloud computing costs | $10.4M | $6.3M | $0 |
| Impairment of property, plant and equipment | $10.6M | $0 | $2.5M |
| Stock-based compensation | $31.6M | $26.3M | $21.5M |
| Deferred income taxes | $17.6M | -$70.6M | $14.3M |
| Trade receivables, net | $44.2M | -$174.7M | $7.0M |
| Inventories | -$6.1M | -$16.5M | -$28.8M |
| Due from/due to Becton, Dickinson and Company | $25.3M | $58.9M | -$23.2M |
| Prepaid expenses and other | $8.5M | $39.5M | -$14.2M |
| Accounts payable, accrued expenses and other current liabilities | -$68.9M | $60.0M | $7.9M |
| Income and other net taxes payable | -$28.1M | $13.2M | -$12.6M |
| Other assets and liabilities, net | $1.4M | -$28.1M | -$16.1M |
| Net Cash Provided by Operating Activities | $191.7M | $35.7M | $67.7M |
| Capital expenditures | -$9.3M | -$15.8M | -$26.5M |
| Net Cash Used for Investing Activities | -$9.3M | -$15.8M | -$26.5M |
| Payments on long-term debt | -$184.6M | -$34.6M | -$9.5M |
| Payments related to tax withholding for stock-based compensation | -$5.7M | -$3.0M | -$3.6M |
| Payments on finance lease | -$1.4M | -$1.3M | -$1.2M |
| Dividend payments | -$35.0M | -$34.5M | -$34.4M |
| Net Cash Used for Financing Activities | -$226.7M | -$73.4M | -$48.7M |
| Effect of exchange rate changes on cash and equivalents and restricted cash | -$1.3M | $1.2M | $3.1M |
| Net Change in Cash and equivalents and restricted cash | -$45.6M | -$52.3M | -$4.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Embecta Corp. sits at the top of its group. 49 entities, 43 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Embecta Corp.
- AMERICAN CENTURY INVESTMENT MANAGEMENT INC Filed SCHEDULE 13G/A on Embecta Corp., latest Aug 14, 2026 (8 filings since Jan 9, 2023)
- BlackRock Filed SCHEDULE 13G/A on Embecta Corp., latest Jul 8, 2026
- River Road Asset Management, LLC Filed SCHEDULE 13G/A on Embecta Corp., latest May 27, 2026 (2 filings since Jan 30, 2024)
- YACKTMAN ASSET MANAGEMENT LP Filed SCHEDULE 13G on Embecta Corp., latest May 5, 2026
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Embecta Corp., latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Embecta Corp., latest Mar 26, 2026 (6 filings since May 10, 2022)
- James E. Flynn Filed SCHEDULE 13G/A on Embecta Corp., latest May 13, 2025 (2 filings since Oct 25, 2024)
- INTEGRATED CORE STRATEGIES (US) LLC Filed SC 13G/A on Embecta Corp., latest Nov 7, 2024 (3 filings since Sep 13, 2023)
- T. Rowe Price Investment Management, Inc. Filed SC 13G/A on Embecta Corp., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
- FMR LLC Filed SC 13G/A on Embecta Corp., latest Feb 9, 2024 (2 filings since Feb 9, 2023)
- State Street Corporation Filed SC 13G/A on Embecta Corp., latest Jan 23, 2024 (4 filings since Nov 10, 2022)
- Embecta Corp. Wilmington, Delaware, United States
- embecta (Thailand) Ltd. Subsidiary · Thailand
- embecta Arabia Limited Co. Subsidiary · Saudi Arabia
- embecta Argentina S.R.L. Subsidiary · Argentina
- embecta Australia Pty Ltd Subsidiary · Australia
- embecta Austria GmbH Subsidiary · Austria
- embecta Belgium BV Subsidiary · Belgium
- embecta Brasil Ltda. Subsidiary · Brazil
- Embecta Canada Co. Subsidiary · Canada
- embecta Colombia S.A.S. Subsidiary · Colombia
- embecta Denmark ApS Subsidiary · Denmark
- embecta Finland Oy Subsidiary · Finland
- embecta France Subsidiary · France
- embecta G.K. Subsidiary · Japan
- embecta Hong Kong Limited Subsidiary · Hong Kong
- embecta India Private Limited Subsidiary · India
- embecta Italy S.r.l. Subsidiary · Italy
- embecta Luxembourg II S.à r.l. Subsidiary · Luxembourg
- embecta Malaysia Sdn. Bhd. Subsidiary · Malaysia
- embecta Medical Devices (Shanghai) Co., Ltd. Subsidiary · China
- embecta Medical Devices (Shanghai) Co., Ltd. Beijing Branch Subsidiary · China
- embecta Medical Devices (Shanghai) Co., Ltd. Pudong Branch Subsidiary · China
- embecta Medical Devices (Suzhou) Co., Ltd. Subsidiary · China
- embecta Medical Spain, S.L. Subsidiary · Spain
- embecta Mexico, S. de R.L. de C.V. Subsidiary · Mexico
- embecta Netherlands B.V. Subsidiary · Netherlands
- and 23 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Embecta Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finance-lease assets | $28.3M3 Sep 30, 2025 | $30.8M3 Sep 30, 2024 | −8.1% |
| Operating-lease assets (leased space) | $20.2M3 Sep 30, 2025 | $22.6M3 Sep 30, 2024 | −10.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $225.5M3 Sep 30, 2025 | $267.5M3 Sep 30, 2024 | −15.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $15.4M3 Sep 30, 2025 | $15.6M3 Sep 30, 2024 | −1.3% |
| Finite-lived intangibles, net | $7.0M3 Sep 30, 2025 | $8.1M3 Sep 30, 2024 | −13.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $178.6M3 Sep 30, 2025 | $171.5M3 Sep 30, 2024 | +4.1% |
| Work in process | $11.7M3 Sep 30, 2025 | $4.8M3 Sep 30, 2024 | +143.8% |
| Finished goods | $116.9M3 Sep 30, 2025 | $126.3M3 Sep 30, 2024 | −7.4% |
Properties, in its own words
Embecta's corporate headquarters is located in Parsippany, New Jersey, USA. The Company also maintains secondary regional headquarters at leased office facilities in Eysins, Switzerland, Shanghai, China and Singapore. Embecta has three manufacturing facilities located in Ireland, the United States, and China which occupy an aggregate of approximately 800,000 square feet of space.
Item 2 of the 10-K filed Nov 25, 2025.6
Leadership
Who has led Embecta Corp., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerDevdatt Kurdikar Feb 10, 2022 to now13
- PresidentDevdatt Kurdikar Feb 10, 2022 to now13
- Chief financial officerJacob Elguicze Feb 10, 2022 to now14
Board members and other officers (17)
- Chief Accounting OfficerAnthony M. Roth Dec 4, 2024 to now15
- Chief Human Resources OfficerJean Casner Jul 19, 2023 to now16
- VP, CAO & Corp. ControllerBrian Capone Apr 6, 2022 to Nov 28, 202317
- SVP, GC, Head Corp. Dev., SecyJeffrey Z. Mann Apr 6, 2022 to now18
- SVP, Global Manuf./Sup. ChainShaun Curtis Apr 6, 2022 to now19
- Board memberGary Defazio Feb 10, 2022 to Feb 10, 202220
- Board memberJoseph Frank Lasala Feb 10, 2022 to Feb 10, 202221
- Board memberStephanie Kelly Feb 10, 2022 to Feb 10, 202222
- Board memberRobert J. Hombach Mar 21, 2022 to now23
- Board memberCarrie L. Anderson Apr 5, 2022 to now24
- Board memberChristopher R. Reidy Apr 5, 2022 to now25
- Board memberClaire Pomeroy Apr 5, 2022 to now26
- Board memberDavid Albritton Apr 5, 2022 to Feb 14, 202527
- Board memberKaren Prange Apr 5, 2022 to now28
- Board memberMilton Mayo Morris Apr 5, 2022 to now29
- Board memberDevdatt Kurdikar Apr 6, 2022 to now30
- General counselJeffrey Z. Mann Aug 13, 2026 to now31
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Embecta Canada Co. Canada5
- embecta (Thailand) Ltd. Thailand5
- embecta Arabia Limited Co. Saudi Arabia5
- embecta Argentina S.R.L. Argentina5
- embecta Australia Pty Ltd Australia (Victoria)5
- embecta Austria GmbH Austria5
- embecta Belgium BV Belgium5
- embecta Brasil Ltda. Brazil5
- embecta Colombia S.A.S. Colombia5
- embecta Denmark ApS Denmark5
- embecta Finland Oy Finland5
- embecta France France (Paris)5
- embecta G.K. Japan (Tokyo)5
- embecta GmbH Germany (Heidelberg)5
- embecta Hong Kong Limited Hong Kong5
- embecta India Private Limited India5
- embecta Italy S.r.l. Italy5
- embecta Luxembourg II S.à r.l. Luxembourg5
- embecta Malaysia Sdn. Bhd. Malaysia5
- embecta Medical Devices (Shanghai) Co., Ltd. China (Shanghai)5
- embecta Medical Devices (Shanghai) Co., Ltd. Beijing Branch China (Beijing)5
- embecta Medical Devices (Shanghai) Co., Ltd. Pudong Branch China (Pudong)5
- embecta Medical Devices (Suzhou) Co., Ltd. China5
- embecta Medical Spain, S.L. Spain5
All 49 listed subsidiaries
- embecta Mexico, S. de R.L. de C.V. Mexico5
- embecta Netherlands B.V. Netherlands (Amsterdam)5
- embecta Netherlands B.V. - Belgian Branch Belgium5
- embecta Netherlands B.V. – Representative Office United Arab Emirates5
- embecta New Zealand Limited New Zealand5
- embecta Norway AS Norway5
- embecta Penel Ltd. Cayman Islands5
- embecta Penel Ltd. Irish Branch Ireland5
- embecta Peru S.R.L. Peru5
- embecta Philippines, Inc. Philippines5
- embecta Poland sp. z o.o. Poland5
- embecta Portugal, Unipessoal Lda Portugal5
- embecta Rus Limited Liability Company Russia5
- embecta Singapore Pte. Ltd. Singapore5
- embecta Singapore Pte. Ltd. Taiwan Branch Taiwan5
- embecta Singapore Pte. Ltd., Indonesia Foreign Trading Representative Office Indonesia5
- embecta South Africa Proprietary Limited South Africa5
- embecta Sweden AB Sweden5
- embecta Switzerland Holdings Sàrl Switzerland (Vaud)5
- embecta Switzerland Sàrl Switzerland (Vaud)5
- embecta Turkey Medikal Ürün ve Cihazlar İthalat İhracat Satış Pazarlama ve Dağıtım Limited Şirketi Turkey5
- embecta U.K. Limited United Kingdom5
- embecta U.K. Limited Irish Branch Ireland5
- embecta Uruguay SRL Uruguay5
- embecta Vietnam Co., Ltd. Vietnam5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Berra Newco, Inc.Jul 15, 2021 to Sep 3, 20214
Timeline
- Aug 7, 20268-K Results of operations32
- Jul 31, 20268-K Financial statements and exhibits33
- May 15, 20268-K Completed an acquisition or sale; Regulation FD disclosure34
- May 5, 20268-K Results of operations35
- Mar 20, 20268-K Entered a material agreement; Regulation FD disclosure36
- Feb 13, 20268-K Shareholder vote37
- Feb 5, 20268-K Results of operations38
- Nov 25, 20258-K Results of operations39
- Nov 17, 20258-K Executive or director change40
- Aug 8, 20258-K Results of operations41
- May 22, 20258-K Regulation FD disclosure42
- May 9, 20258-K Results of operations43
- Feb 10, 2022New chief executive Devdatt Kurdikar becomes CEO13
- Jul 8, 2021Founded Embecta Corp. is founded2
Calendar
Coming up
- Nov 24, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.50 a share, on Nov 25, 2025.44
When it reported results
- Aug 7, 2026Reported quarterly or annual results32
- May 5, 2026Reported quarterly or annual results35
- Feb 5, 2026Reported quarterly or annual results38
- Nov 25, 2025Reported quarterly or annual results39
- Aug 8, 2025Reported quarterly or annual results41
- May 9, 2025Reported quarterly or annual results43
- Feb 6, 2025Reported quarterly or annual results45
- Nov 26, 2024Reported quarterly or annual results46
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
257 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 39 major events, 130 insider forms, 36 large holders, 32 other. The latest 20:
- Sep 8, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 11, 20264 EDGAR
- Aug 7, 202610-Q EDGAR
- Aug 7, 20268-K EDGAR
- Aug 7, 2026S-8 REGISTRATION STATEMENT EDGAR
- Jul 31, 20268-K/A EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jun 2, 20264 EDGAR
- May 27, 2026SCHEDULE 13G/A EDGAR
- May 22, 2026SD EDGAR
- May 15, 20268-K CURRENT REPORT EDGAR
- May 5, 202610-Q EDGAR
- May 5, 20268-K EDGAR
- May 5, 2026SCHEDULE 13G EDGAR
The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
15 open-market trades by officers, directors and large owners since October 2021: 13 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Morris Milton MayoDirector | Sale | 6,293 | $5.88 | $37.0K | Form 4 |
| Aug 12, 2026 | Kurdikar DevdattPresident and CEO | Buy | 30,000 | $4.70 | $141.0K | Form 4 |
| Aug 12, 2026 | Elguicze JacobSVP and CFO | Buy | 20,000 | $4.67 | $93.4K | Form 4 |
| Aug 12, 2026 | Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO | Buy | 20,000 | $4.99 | $99.8K | Form 4 |
| Aug 12, 2026 | HOMBACH ROBERT J.Director | Buy | 45,000 | $4.97 | $223.7K | Form 4 |
| May 23, 2025 | Melcher David FDirector | Buy | 10,000 | $10.60 | $106.0K | Form 4 |
| Feb 25, 2025 | Melcher David FDirector | Buy | 13,000 | $13.67 | $177.7K | Form 4 |
| Feb 13, 2025 | Morris Milton MayoDirector | Sale | 3,100 | $16.38 | $50.8K | Form 4 |
| Feb 12, 2024 | Melcher David FDirector | Buy | 2,000 | $16.25 | $32.5K | Form 4 |
| Sep 8, 2023 | Melcher David FDirector | Buy | 6,233 | $15.77 | $98.3K | Form 4 |
| Aug 10, 2023 | Kurdikar DevdattPresident and CEO | Buy | 5,000 | $21.81 | $109.0K | Form 4 |
| Aug 10, 2023 | Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO | Buy | 4,700 | $21.67 | $101.8K | Form 4 |
| Aug 10, 2023 | Elguicze JacobSVP and CFO | Buy | 4,625 | $21.66 | $100.2K | Form 4 |
| Feb 15, 2023 | Melcher David FDirector | Buy | 3,100 | $32.93 | $102.1K | Form 4 |
| Feb 15, 2023 | Melcher David FDirector | Buy | 3,100 | $32.51 | $100.8K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- AMERICAN CENTURY INVESTMENT MANAGEMENT INCSCHEDULE 13G/A, 8 filings Jan 9, 2023 to Aug 14, 202647
- BlackRockSCHEDULE 13G/A, 1 filing Jul 8, 202648
- River Road Asset Management, LLCSCHEDULE 13G/A, 2 filings Jan 30, 2024 to May 27, 202649
- YACKTMAN ASSET MANAGEMENT LPSCHEDULE 13G, 1 filing May 5, 202650
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202651
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings May 10, 2022 to Mar 26, 202652
- James E. FlynnSCHEDULE 13G/A, 2 filings Oct 25, 2024 to May 13, 202553
- INTEGRATED CORE STRATEGIES (US) LLCSC 13G/A, 3 filings Sep 13, 2023 to Nov 7, 202454
- T. Rowe Price Investment Management, Inc.SC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202455
- FMR LLCSC 13G/A, 2 filings Feb 9, 2023 to Feb 9, 202456
- State Street CorporationSC 13G/A, 4 filings Nov 10, 2022 to Jan 23, 202457
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Dev KurdikarDirector, Chief Executive Officer and President | 57 | $976.9K | $9.4M58 |
| 2025 | Jake ElguiczeSenior Vice President and Chief Financial Officer | $603.1K | $3.5M58 | |
| 2025 | Jeff MannSenior Vice President, General Counsel and Product Development | $600.8K | $3.0M58 | |
| 2025 | Shaun CurtisSenior Vice President, Global Manufacturing, Supply Chain and Quality | $580.4K | $2.1M58 | |
| 2025 | Jean CasnerSenior Vice President, Chief Human Resources Officer | $480.4K | $1.7M58 | |
| 2024 | Dev KurdikarDirector, Chief Executive Officer and President | 57 | $894.2K | $8.6M58 |
| 2024 | Jake ElguiczeSenior Vice President and Chief Financial Officer | $557.2K | $3.1M58 | |
| 2024 | Jeff MannSenior Vice President, General Counsel and Product Development | $553.4K | $2.6M58 | |
| 2024 | Shaun CurtisSenior Vice President, Global Manufacturing, Supply Chain and Quality | $504.5K | $1.7M58 | |
| 2024 | Jean CasnerSenior Vice President, Chief Human Resources Officer | $455.8K | $1.3M58 | |
| 2023 | Dev KurdikarDirector, Chief Executive Officer and President | 57 | $863.5K | $7.5M58 |
| 2023 | Jake ElguiczeSenior Vice President and Chief Financial Officer | $528.8K | $2.6M58 | |
| 2023 | Jeff MannSenior Vice President, General Counsel and Product Development | $528.8K | $2.2M58 | |
| 2023 | Shaun CurtisSenior Vice President, Global Manufacturing, Supply Chain and Quality | $459.4K | $1.5M58 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,599,771 | $15.0M | 0.0% | −4,567,441 |
| Yacktman Asset Management LP | 4,315,952 | $14.1M | 0.2% | +644,075 |
| Vanguard Capital Management LLC | 2,557,148 | $8.3M | 0.0% | −6,803 |
| Deerfield Management Company, L.P. | 2,534,961 | $8.3M | 0.1% | No change |
| Jefferies Financial Group Inc. | 2,355,117 | $7.7M | 0.1% | −45 |
| Ameriprise Financial Inc | 2,038,731 | $6.6M | 0.0% | +1,239,043 |
| Morgan Stanley | 1,996,747 | $6.5M | 0.0% | +1,386,943 |
| State Street Corp | 1,610,666 | $5.3M | 0.0% | −935,307 |
| Geode Capital Management, LLC | 1,594,457 | $5.2M | 0.0% | +128,810 |
| Brigade Capital Management, LP | 1,516,453 | $4.9M | 5.7% | New |
| Goldman Sachs Group Inc | 1,162,041 | $3.8M | 0.0% | +413,586 |
| Vanguard Portfolio Management LLC | 1,098,389 | $3.6M | 0.0% | −439,568 |
| Charles Schwab Investment Management Inc | 1,069,786 | $3.5M | 0.0% | −122,247 |
| Jacobs Levy Equity Management, Inc | 1,027,514 | $3.3M | 0.0% | New |
| Aqr Capital Management LLC | 976,587 | $3.2M | 0.0% | +644,984 |
| Millennium Management LLC | 945,968 | $3.1M | 0.0% | −648,177 |
| UBS Group AG | 829,099 | $2.7M | 0.0% | +399,049 |
| D. E. Shaw & Co., Inc. | 650,070 | $2.1M | 0.0% | +117,742 |
| Royce & Associates LP | 639,378 | $2.1M | 0.0% | +575,818 |
| Bank of New York Mellon Corp | 581,480 | $1.9M | 0.0% | −242,307 |
| Northern Trust Corp | 558,886 | $1.8M | 0.0% | −63,038 |
| Allianz Asset Management GmbH | 527,109 | $1.7M | 0.0% | +190,178 |
| Atom Investors LP | 500,470 | $1.6M | 0.1% | +455,280 |
| Vanguard Global Advisers, LLC | 485,170 | $1.6M | 0.0% | +304,791 |
| Citadel Advisors LLC | 446,091 | $1.5M | 0.0% | +54,272 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Embecta Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAREmbecta Corp.1
- CIK0001872789
- Employer ID (EIN)87-15839426
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsSeptember 301
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address300 Kimball Drive, Suite 300, Parsippany, NJ 070541
- Phone86240100001
- Shares outstanding56,659,599 as of Jul 31, 202612
- Public float$732.0M as of Mar 31, 20256
- AuditorERNST & YOUNG LLP, New York, New York PCAOB ID 42; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceJul 15, 20211
- Filings262 in all: 4 (99), 8-K (38), 3 (20), 10-Q (15), SC 13G/A (14), SCHEDULE 13G/A (11), SC 13G (10), 4/A (9)1
All 29 form types
DEFA14A (5), 10-K (4), DEF 14A (4), SD (4), UPLOAD (4), ARS (3), CORRESP (3), S-8 (3), 144 (2), 3/A (2), SCHEDULE 13G (2), 10-12B (1), 10-12B/A (1), 10-K/A (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-K (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (10-K) Nov 25, 2025
Quarterly report (10-Q) Aug 7, 2026
Proxy statement (DEF 14A) Dec 18, 2025
Latest 8-K (8-K) Aug 7, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.01 per share | EMBC | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Nov 25, 2025 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Embecta Corp. names in Item 1A of its 10-K filed Nov 25, 2025: 50 risks under these headings, as written.6
- Risks Related to Embecta’s Business
- Risks Related to the Separation and Distribution from BD
- Risks Related to Embecta’s Common Stock
- The medical technology industry is very competitive.
- Embecta generates a significant amount of its profits and cash flows from a few key products, and any events that adversely affect the sale or profitability of these products could have an adverse impact on Embecta’s sales, results of operations and cash flows.
- Technological breakthroughs in diabetes treatment or prevention may reduce demand for Embecta’s products.
- Embecta obtains components, services and raw materials for its products from third parties, including BD. These third parties may fail to perform under their agreements with Embecta, or there may be a reduction, interruption, or termination in the manufacturing and supply of these components and raw materials. Any such failure to perform or a reduction, interruption, or termination in supply could have a material adverse effect on Embecta’s business and operations.
- Embecta may experience difficulties and delays in the manufacturing of its products or sterilization operations, and any such difficulties and delays could adversely affect Embecta’s business.
- A substantial portion of Embecta’s revenue is derived from sales to a few customers. If these customers reduce the amount of product that they purchase from Embecta, reduce the amount that they are willing to pay for such products or increase charges to distribute such products, Embecta’s business, financial condition and results of operations could be adversely affected.
- Embecta’s products are subject to continuous reimbursement, coverage and access scrutiny by both private and government payers, including the scope of products covered, access and coverage among product brands and manufacturers, reimbursement limitations and price adjustment restrictions. A change in any of these factors could have an adverse impact on Embecta’s financial condition and results of operations.
- Embecta may enter into strategic collaborations, in-licensing arrangements or alliances with third parties that may not result in the development of commercially viable products or the generation of revenue.
- Embecta’s sales and marketing efforts rely upon independent distributors that are free to market products that compete with Embecta’s products, and if Embecta is unable to maintain or expand its network of independent distributors, its business could be materially adversely affected.
The other 41 risks
- Embecta’s future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed or be successful.
- Embecta’s failure to maintain strong relationships with physicians and other healthcare professionals could adversely affect its business.
- Embecta may not be able to successfully execute its acquisition strategy, which could adversely affect its financial condition and results of operations.
- Embecta’s international operations subject it to certain business risks.
- Trade actions, such as tariffs, retaliatory tariffs, and private or governmental "buy local" initiatives could adversely and unexpectedly impact our business.
- If the third parties on which Embecta relies to conduct its clinical trials and to assist it with pre-clinical development do not perform as contractually required or expected, or if market or clinical or other studies are unfavorable to its products in development, Embecta may not be able to obtain regulatory clearance or approval or commercialize its products.
- Embecta’s business and operations are subject to risks related to climate change.
- Embecta's business could be negatively impacted by evolving regulations, policies and expectations relating to ESG initiatives, setting related goals, collecting data and disclosing related information.
- Foreign currency exchange rate, inflation, commodity price, energy and oil prices and supply, and interest rate fluctuations may adversely affect Embecta’s financial condition and results of operations.
- Fluctuations in Embecta’s effective tax rate and changes to tax laws may adversely affect it.
- If Embecta fails to protect its intellectual property or proprietary technology, such failure could adversely affect its business and results of operations.
- Embecta’s products or processes may infringe the intellectual property rights of others, which may cause Embecta to pay unexpected litigation costs, damages, or settlement fees (including royalties) or prevent Embecta from selling its products.
- Breaches of Embecta’s Information Systems and cyberattacks aimed at accessing Embecta’s devices, products and services or related devices, products and services could have a material adverse effect on its operations.
- Embecta needs to attract and retain key employees to be competitive.
- Embecta’s business may be adversely affected by work stoppages, union negotiations and labor disputes.
- Embecta is subject to extensive regulation.
- Healthcare reform may have a material adverse effect on Embecta’s financial condition and results of operations.
- Certain modifications to Embecta’s products may require new 510(k) clearances or other marketing authorizations and may require Embecta to recall or cease marketing its products.
- Embecta may be subject to enforcement actions if it engages in improper marketing or promotion of its products.
- Changes in government funding for the FDA and other government agencies could affect their ability to obtain and retain key resources and personnel, properly administer medical device innovation, or prevent Embecta’s products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing routine business functions on which the operation of Embecta’s business relies, which could adversely affect its business.
- Embecta is subject to complex and evolving laws and regulations regarding privacy and data protection, many of which are subject to change and uncertain interpretation, which could result in claims, changes to its business practices, penalties, increased cost of operations or declines in user growth or engagement, or otherwise adversely affect its business.
- A disruption at one of Embecta's facilities could adversely affect our business and operating results.
- Insurance coverage may be inadequate or unavailable to cover any product liability losses Embecta incurs.
- Embecta is subject to a number of restrictive covenants under its indebtedness, including customary operating restrictions and financial covenants, which could restrict Embecta's ability to pay dividends or adversely affect its financing options and liquidity position.
- Embecta is subject to risks associated with public health threats, such as pandemics, which could have a material adverse effect on Embecta's financial condition and results of operation.
- Risks Related to the Separation from BD
- Embecta has a limited history of operating as an independent company, and its historical financial information may not be a reliable indicator of its future results.
- Since the Separation, Embecta’s financial profile has changed, and it is a smaller, less diversified company than BD prior to the Separation.
- Embecta may not achieve some or all of the expected benefits of the Separation.
- Following the end of the transition period, Embecta will be required to rebrand its products to remove the BD name, transfer or obtain new manufacturing, supply chain, regulatory and product licenses and registrations in the name of Embecta, which could adversely affect its ability to attract and maintain customers and end users or which could result in delays or interruptions of Embecta's commercialization and distribution operations or the loss of customers and revenue, all of which could adversely affect its financial condition and results of operations.
- Embecta has incurred debt obligations that could adversely affect its business and profitability and its ability to meet other obligations.
- Embecta may be affected by significant restrictions under the tax matters agreement, in order to avoid triggering significant tax-related liabilities.
- Embecta may be held liable to BD if it fails to perform under its agreements with BD, and the performance of such services may negatively affect Embecta’s business and operations.
- Embecta’s agreements with BD may be on terms that are less beneficial to Embecta than the terms may have otherwise been from unaffiliated third parties.
- If there is a determination that the distribution or certain related transactions are taxable for United States federal income tax purposes, BD and its stockholders could incur significant tax liabilities, and Embecta could incur significant liabilities pursuant to its indemnification obligations under the tax matters agreement.
- The transfer to Embecta of certain contracts, permits and other assets and rights may require the consents, approvals of, or provide other rights to, third parties and governmental authorities. If such consents or approvals are not obtained, Embecta may not be entitled to the full benefit of such contracts, permits and other assets and rights, which could increase its expenses or otherwise harm its business and financial performance.
- Satisfaction of indemnification obligations could have a material adverse effect on Embecta’s financial condition, results of operations and cash flows.
- Risks Related to Embecta Common Stock
- The price of Embecta common stock may fluctuate significantly, and stockholders could lose all or part of their investment in Embecta.
- Your percentage of ownership in Embecta may be diluted in the future.
- Embecta cannot guarantee the timing, amount or payment of dividends on its common stock.
- Anti-takeover provisions could enable Embecta’s Board of Directors to resist a takeover attempt by a third-party and limit the power of its stockholders.
- Embecta’s amended and restated certificate of incorporation designates the state courts within the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by Embecta stockholders, which could discourage lawsuits against Embecta and its directors and officers.
Legal proceedings
We are from time to time subject to claims and litigation arising in the ordinary course of business. These claims and litigation may include, among other things, allegations of violations of United States and foreign health regulation and privacy laws and related regulations, as well as claims or litigation relating to product liability, intellectual property, breach of contract and tort, environmental, securities and employment matters. We operate in multiple jurisdictions and, as a result, claims in one jurisdiction may lead to claims or regulatory penalties in other jurisdictions. There can be no assurance as to the ultimate outcome of a legal proceeding; however, we intend to defend vigorously against any pending or future claims and litigation, other than matters deemed appropriate for settlement. We accrue a liability for legal claims when payments associated with the claims become probable and the costs can be reasonably estimated. The actual costs of
resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. As of September 30, 2025, we were not a party to or subject to any material proceedings.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGAREmbecta Corp. filings on SEC EDGAR
- 2
- 3SEC EDGAREmbecta Corp. 10-K for fiscal 2025
- 4SEC EDGAREmbecta Corp. filings on SEC EDGAR
- 5
- 6
- 7SEC EDGAREmbecta Corp. 10-K for fiscal 2020
- 8SEC EDGAREmbecta Corp. 10-K for fiscal 2021
- 9SEC EDGAREmbecta Corp. 10-K for fiscal 2022
- 10SEC EDGAREmbecta Corp. 10-Q for fiscal 2025
- 11SEC EDGAREmbecta Corp. 10-Q for fiscal 2026
- 12SEC EDGAREmbecta Corp. 10-Q for fiscal 2026
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARGary Defazio, Board member
- 21SEC EDGARJoseph Frank Lasala, Board member
- 22SEC EDGARStephanie Kelly, Board member
- 23SEC EDGARRobert J. Hombach, Board member
- 24SEC EDGARCarrie L. Anderson, Board member
- 25SEC EDGARChristopher R. Reidy, Board member
- 26SEC EDGARClaire Pomeroy, Board member
- 27SEC EDGARDavid Albritton, Board member
- 28SEC EDGARKaren Prange, Board member
- 29SEC EDGARMilton Mayo Morris, Board member
- 30SEC EDGARDevdatt Kurdikar, Board member
- 31SEC EDGARJeffrey Z. Mann, General counsel
- 32SEC EDGARResults of operations
- 33SEC EDGARFinancial statements and exhibits
- 34
- 35SEC EDGARResults of operations
- 36
- 37SEC EDGARShareholder vote
- 38SEC EDGARResults of operations
- 39SEC EDGARResults of operations
- 40SEC EDGARExecutive or director change
- 41SEC EDGARResults of operations
- 42SEC EDGARRegulation FD disclosure
- 43SEC EDGARResults of operations
- 44NasdaqNasdaq calendar
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56SEC EDGARFMR LLC SC 13G/A on Embecta Corp.
- 57
- 58